Observational Studies Reveal Commonalities Across Neurodegenerative Disorders Like Parkinson’s And Alzheimer’s
This article was originally published in Pharmaceutical Approvals Monthly
It’s all about biomarkers, biomarkers, biomarkers as huge cohort studies amass data in the hunt for clues that can aid in drug development, and the rising tide may lift more than one boat as commonalities among diseases like Alzheimer’s and Parkinson’s are discovered.
You may also be interested in...
Researchers have shown that a new class of small molecule can inhibit assembly of the protein alpha-synuclein into toxic clumps, a hallmark of Parkinson’s disease. Their work supports other ongoing investigations suggesting that the compound may be useful as a neuroprotective agent for treating a range of diseases characterized by the clumping of amyloid proteins, including Alzheimer’s disease, various types of amyloidosis, and prion disease.
Biomarkers For Alzheimer's, Parkinson's Disease To Be Developed By Industry Coalition Through First-Of-A-Kind Clinical Data Exchange
Unable to defeat Alzheimer's Disease and Parkinson's Disease, companies have joined forces to come up with new research tools
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.